Table 4. One-year clinical outcomes in propensity score matched patients.
| Outcomes | SS PCI (n=162) | MS PCI (n=162) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI)* | p value | HR (95% CI)† | p value | ||||
| 30 days outcomes | |||||||
| MACE | 8/162 (4.9) | 6/162 (3.7) | 0.75 (0.26–2.15) | 0.586 | 0.71 (0.23–2.16) | 0.546 | |
| All-cause mortality | 4/162 (2.5) | 2/162 (1.2) | 0.50 (0.09–2.72) | 0.420 | 0.67 (0.07–6.16) | 0.725 | |
| Cardiac death | 3/162 (1.9) | 2/162 (1.2) | 0.66 (0.11–3.97) | 0.653 | 1.22 (0.12–12.05) | 0.865 | |
| 30 days to 1-year outcomes‡ | |||||||
| MACE | 15/154 (9.7) | 9/156 (5.8) | 0.53 (0.24–1.25) | 0.146 | 0.46 (0.19–1.12) | 0.087 | |
| All-cause mortality | 6/158 (3.8) | 3/160 (1.9) | 0.49 (0.12–1.96) | 0.314 | 0.40 (0.09–1.78) | 0.230 | |
| Cardiac death | 5/159 (3.1) | 1/160 (0.6) | 0.19 (0.02–1.65) | 0.133 | 0.13 (0.01–1.31) | 0.083 | |
| 1-year outcomes | |||||||
| MACE | 23/162 (14.2) | 15/162 (9.3) | 0.60 (0.31–1.17) | 0.137 | 0.48 (0.24–0.96) | 0.038 | |
| All-cause mortality | 10/162 (6.2) | 5/162 (3.1) | 0.49 (0.17–1.44) | 0.197 | 0.37 (0.12–1.24) | 0.111 | |
| Cardiac death | 8/162 (4.9) | 3/162 (1.9) | 0.37 (0.10–1.38) | 0.138 | 0.26 (0.06–1.13) | 0.072 | |
| Non-cardiac death | 2/162 (1.2) | 2/162 (1.2) | 1.01 (0.14–7.19) | 0.990 | 1.80 (0.19–16.95) | 0.609 | |
| Myocardial infarction | 5/162 (3.1) | 5/162 (3.1) | 0.79 (0.21–2.94) | 0.726 | 0.72 (0.26–1.99) | 0.527 | |
| TVR/TLR | 6/162 (3.7) | 4/162 (2.5) | 0.67 (0.19–2.38) | 0.535 | 0.59 (0.16–2.17) | 0.429 | |
| Stroke | 4/162 (2.5) | 1/162 (0.6) | 0.24 (0.03–2.19) | 0.208 | 0.07 (0.01–1.66) | 0.098 | |
Values are number (%) for categorical values.
MACE = major adverse cardiovascular event; MS PCI = multi-staged percutaneous coronary intervention; SS PCI = single-staged percutaneous coronary intervention; TLR = target lesion revascularization; TVR = target vessel revascularization.
*HR are for the multi-vessel MS PCI groups compared with multi-vessel SS PCI group; †Adjusted Cox hazard regression analysis included various clinical variables including age, sex, use of statin, left ventricular ejection fraction, Initial Killip class (I-II vs. III-IV), and Target vessel; ‡Subjects who had an adverse events in initial 30 days were excluded in 30 days to 1-year outcomes data. Cox hazard regression analysis also included same variables used in 30 days outcomes and 1-year outcomes.